CD4+ T cell plasticity engenders robust immunity in response to cytokine therapy

Megan E Nelles; Christopher J Paige

doi:10.4161/2162402X.2014.994370

CD4⁺ T cell plasticity engenders robust immunity in response to cytokine therapy

Oncoimmunology. 2015 Jan 22;4(3):e994370. doi: 10.4161/2162402X.2014.994370. eCollection 2015 Mar.

Authors

Megan E Nelles¹, Christopher J Paige²

Affiliations

¹ Ontario Cancer Institute; Princess Margaret Cancer Centre; University Health Network ; Toronto, Ontario, Canada ; Department of Medical Biophysics; University of Toronto ; Toronto, Ontario, Canada.
² Ontario Cancer Institute; Princess Margaret Cancer Centre; University Health Network ; Toronto, Ontario, Canada ; Department of Medical Biophysics; University of Toronto ; Toronto, Ontario, Canada ; Department of Immunology; University of Toronto ; Toronto, Ontario, Canada.

Abstract

CD4⁺ T cells represent an entire arm of the immune system that has hitherto been incompletely understood, but their potential to act as both helper and effector may make them optimal protagonists in immunotherapeutic approaches to treat cancer. Cytokine therapy can activate this population in a manner that ensures maximal diversification of effector function for a robust immune response.

Keywords: ACT, adoptive cell therapy; Ag, antigen; CAR, chimeric antigen receptor; CD4+ CTL; CTL, cytotoxic T lymphocyte; DC, dendritic cell; GzmB, granzyme B; IL-12; IL-12, interleukin-12; NKT; NKT, natural killer T cell; ThPOK; cytokine therapy; cytotoxicity; immunotherapy.